AstraZeneca's Sir Pascal Soriot confirms the company is no longer pursuing a potential takeover of Bristol Myers Squibb.
Sir Pascal Soriot, the chief executive of AstraZeneca, is overseeing a company that has moved past preliminary talks regarding a potential takeover of US rival Bristol Myers Squibb. While the UK firm's shares initially plunged 9% following reports of the merger, the share price saw a relief rally after Reuters confirmed there are no ongoing discussions. Soriot has led AstraZeneca with a focus on long-term success and internal innovation rather than debt-heavy, short-term cost-cutting mergers. Analysts note that while both companies are leaders in oncology, the timing of the market conditions and Bristol Myers Squibb's upcoming patent expirations made the deal appear unconventional. Shareholders are now looking for more transparency from Soriot regarding whether the company will continue to pursue mega-deals in the future or maintain its current strategy of focusing on its own laboratory successes.